THE ASSESSMENT OF COMPENSATION OF CARBOHYDRATE METABOLISM IN PATIENTS WITH TYPE 2 DIABETES MELLITUS WITH METABOLIC SYNDROME BEYOND THE LIMITS OF GLYCATED HEMOGLOBIN

Abstract

The aim: To investigate glycemic variability in type 2 diabetes patients with metabolic syndrome (MS) and to assess its effect on diabetes compensation. Materials and methods: We used traditional indicators of glycemia variability according to the recommendations of the American Diabetes Association Professional Practice Committee. We proved that patients with type 2 diabetes mellitus with MS reliably have worse CGM indicators: Time in range TIR: (3.9–10.0 mmol/l) – 53.30±5.90%; Time above range (TAR): (time above range) (>10.1 mmol/l) – 43.33±5.96%; Time above TAR range (>13.9 mmol/l) – 22.1±3.91%; Glucose Variability СV – 44.10±4.89% compared to patients with type 2 diabetes without MS, which proves the negative effect of insulin resistance on compensation of diabetes. Results: Determination of the level of EI in the blood, calculation of the Caro index, HOMA-IR are informative for verifying the presence of IR in patients with type 2 diabetes with MS. For optimal diabetes control, in addition to HbA1c, we must consider CGM data and % Time in range (TIR). Conclusions: TIR should be used as a target point and an indicator of glycemic control in routine clinical practice. TIR provides accurate data on a patient’s glycemic status and helps better control diabetes.